CN114903799A - 一种用于抗皱嫩肤的微针及其制备方法和应用 - Google Patents
一种用于抗皱嫩肤的微针及其制备方法和应用 Download PDFInfo
- Publication number
- CN114903799A CN114903799A CN202210665048.9A CN202210665048A CN114903799A CN 114903799 A CN114903799 A CN 114903799A CN 202210665048 A CN202210665048 A CN 202210665048A CN 114903799 A CN114903799 A CN 114903799A
- Authority
- CN
- China
- Prior art keywords
- microneedle
- patch
- microneedles
- parts
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000037303 wrinkles Effects 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 30
- 230000001153 anti-wrinkle effect Effects 0.000 claims abstract description 12
- 239000002537 cosmetic Substances 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 8
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 6
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 5
- -1 polydimethylsiloxane Polymers 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 230000003716 rejuvenation Effects 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 14
- 102000008186 Collagen Human genes 0.000 abstract description 12
- 108010035532 Collagen Proteins 0.000 abstract description 12
- 229920001436 collagen Polymers 0.000 abstract description 11
- 229920002385 Sodium hyaluronate Polymers 0.000 abstract description 9
- 229940010747 sodium hyaluronate Drugs 0.000 abstract description 9
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 abstract description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract description 7
- 229930003268 Vitamin C Natural products 0.000 abstract description 7
- 235000019154 vitamin C Nutrition 0.000 abstract description 7
- 239000011718 vitamin C Substances 0.000 abstract description 7
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract description 5
- 235000005152 nicotinamide Nutrition 0.000 abstract description 3
- 229960003966 nicotinamide Drugs 0.000 abstract description 3
- 239000011570 nicotinamide Substances 0.000 abstract description 3
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 25
- 210000003491 skin Anatomy 0.000 description 18
- 108010075016 Ceruloplasmin Proteins 0.000 description 5
- 102100023321 Ceruloplasmin Human genes 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical group OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960005188 collagen Drugs 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VWVRASTUFJRTHW-UHFFFAOYSA-N 2-[3-(azetidin-3-yloxy)-4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound O=C(CN1C=C(C(OC2CNC2)=N1)C1=CN=C(NC2CC3=C(C2)C=CC=C3)N=C1)N1CCC2=C(C1)N=NN2 VWVRASTUFJRTHW-UHFFFAOYSA-N 0.000 description 1
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- XXZCIYUJYUESMD-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(morpholin-4-ylmethyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CN1CCOCC1 XXZCIYUJYUESMD-UHFFFAOYSA-N 0.000 description 1
- LPZOCVVDSHQFST-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CC LPZOCVVDSHQFST-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000530268 Lycaena heteronea Species 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Natural products OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical group [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 125000002523 retinol group Chemical group 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0053—Methods for producing microneedles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明提供了一种用于抗皱嫩肤的微针,所述微针上负载有活性成分,所述活性成分包括以下重量份数的成分:透明质酸钠为5.0~15.0份;重组胶原蛋白为0.5~2.0份;烟酰胺为2.0~10.0份;维生素C为2.0~10.0份;蓝铜胜肽为0.1~0.5份。本发明还提供了上述微针的制备方法及其在美容产品中的应用。本发明的微针可有效祛除皱纹,嫩滑肌肤,达到良好的抗皱嫩肤效果。本发明上述微针的制备方法操作简单,生产成本低,且易于实现连续化大量生产。
Description
技术领域
本发明涉及化妆品美容领域,具体来说,涉及一种用于抗皱嫩肤的微针及其制备方法和应用。
背景技术
目前,微针技术在美容领域和皮肤给药领域得到了广泛应用。微针是一种由金属、硅、聚合物等材料制成、长度为25~2000μm、针尖呈对称圆锥形或非对称斜面形的微米级的阵列结构。可溶性微针一般由可生物溶解或降解的高分子材料制备而成,包覆在可溶性微针里的生物活性物质随着可溶性材料在皮肤里的溶解而逐渐释放出来发挥作用。可溶性微针比不可溶性微针具有更好的生物相容性及更大的载药量,受到了越来越多的关注和研究。可溶性微针膜也已经在欧美、日韩等地广泛使用,例如,应用于对抗皮肤老化、淡化皱纹、修复纤维弹性、治疗痤疮、去除死皮等。
然而,目前市场上尚未发现具有良好的抗皱嫩肤效果的微针。因此,在该领域还有改善的空间。
发明内容
针对现有技术的上述不足之处,本发明的一个目的在于提供一种用于抗皱嫩肤的微针,其可有效祛除皱纹,嫩滑肌肤,达到良好的抗皱嫩肤效果。
为了实现上述目的,本发明提供了一种用于抗皱嫩肤的微针,所述微针上负载有活性成分,所述活性成分包括以下重量份数的成分:
在一个实施例中,所述活性成分包括以下重量份数的组分:
上述微针以透明质酸钠作为微针的主要赋形材料,具有良好的细胞相容性。该微针的针尖负载有重组胶原蛋白、烟酰胺、维生素C、蓝铜胜肽等抗皱嫩肤的活性成分,能够借助微针刺穿皮肤角质层所形成的微通道,将上述活性成分深层递送到皮下,对皮肤起到较好的抗皱嫩肤效果。而且,这些活性成分能够产生协同作用,产生良好的抗皱嫩肤效果。
本发明的另一个目的在于提供上述微针的制备方法。
为了实现上述目的,本发明提供了上述微针的制备方法,包括以下步骤:
(1)微针溶液的制备:
将所述活性成分加入水中,充分搅拌至溶解,配制成微针溶液;
(2)微针的制备:
将上述微针溶液转移至微针模具中;将模具放入真空干燥箱中抽真空,以去除气泡;干燥;将微针从模具上剥离脱模,即得微针。
在一个实施例中,所述模具为聚二甲基硅氧烷微针模具。
在一个实施例中,在步骤(2)中,抽真空之后,去除溢出模具孔槽的溶液,再进行干燥。
在一个实施例中,在步骤(2)中,所述抽真空的参数条件为:真空度为-60~-90kPa,优选为-80kPa,保持3±1小时,优选为3小时。
在一个实施例中,在步骤(2)中,所述干燥步骤在避光和3-5℃的环境中进行;优选地,所述干燥步骤在4℃的环境中进行。
本发明的上述方法操作简单,生产成本低,且易于实现连续化大量生产。
本发明的又一个目的在于提供上述微针在美容产品中的应用。
为了实现上述目的,本发明提供了上述微针在美容产品中的应用,例如可以应用于面膜、手膜、眼膜中。
在一个实施例中,所述美容产品为微针贴,所述微针贴包括基底和若干所述微针,所述微针呈圆锥状,并与所述基底一体成型。
在一个实施例中,所述微针贴还包括贴膜,所述微针贴通过所述基底固定于所述贴膜上,且所述贴膜可与该微针贴的作用部位黏贴固定。
可以理解的是,该贴膜采用常规技术中的贴膜即可,如水凝胶贴膜或医用胶布贴膜等;所述微针贴的作用部位根据其用途而定,如皮肤等。
与现有技术相比,本发明具有以下技术效果:
本发明的微针以透明质酸钠为主要赋形材料,具有良好的细胞相容性;针尖负载有重组胶原蛋白、烟酰胺、维生素C、蓝铜胜肽等抗皱嫩肤的活性成分,且微针可刺穿皮肤角质层,形成微通道,将上述活性成分深层递送到皮下,对皮肤起到较好的抗皱嫩肤效果;而且,重组胶原蛋白、烟酰胺、维生素C、蓝铜胜肽等活性成分能够产生协同作用,进一步增强了微针的抗皱嫩肤效果。
本发明的微针的制备方法操作简单,生产成本低,且易于实现连续化大量生产。
附图说明
图1示出了本发明的微针的制备方法流程图。
图2示出了本发明实施例1中的微针贴(眼膜)的宏观图像。
图3示出了本发明实施例1中的微针的显微图像。
图4示出了本发明实施例1所制备的微针的力学性能评价结果。
具体实施方式
为了便于理解本发明,下面将参照相关附图对本发明进行更全面的描述。附图中给出了本发明的较佳实施例。但是,本发明可以以许多不同的形式来实现,并不限于本文所描述的实施例。相反地,提供这些实施例的目的是使对本发明的公开内容的理解更加透彻全面。
除非另有定义,本文所使用的所有的技术和科学术语与属于本发明的技术领域的技术人员通常理解的含义相同。本文中在本发明的说明书中所使用的术语只是为了描述具体的实施例的目的,不是旨在于限制本发明。本文所使用的术语“和/或”包括一个或多个相关的所列项目的任意的和所有的组合。
以下实施例中所用试剂,如非特别说明,均为市售可得;以下实施例中所用方法,如非特别说明,均为常规方法可实现。
重组胶原蛋白:购自广州启点生物科技有限公司,为I&III嵌合型重组胶原蛋白,货号:QD-A-0619-01。该I&III嵌合型重组胶原蛋白以人I型和III型胶原蛋白基因为模板,构建重组胶原蛋白基因表达载体,并在细胞中高效表达,通过生物分离技术纯化重组胶原蛋白。
实施例
本实施例按照下表1中的活性成分的量,制备不同的微针贴(眼膜),制备方法流程如图1所示,具体步骤如下:
(1)按照表1中所示出的各个成分的量,分别称取各个成分,然后使用纯化水将上述各个成分溶解,并通过均质搅拌器均质混匀,配制成100ml的溶液。接着,对溶液进行1500rpm、10min的离心消泡,检测溶液的pH值,得到具有不同活性成分含量的一系列微针溶液(如图1中I所示)。
(2)将步骤1)配制的微针溶液转移到聚二甲基硅氧烷(PDMS)微针模具中(如图1中II所示),然后将聚二甲基硅氧烷微针模具放入真空干燥箱中以去除气泡,抽真空至-80KPa,保持真空度持续约3小时,确保气泡已经完全去除(如图1中III所示)。然后,去除溢出模具孔槽的微针溶液,也即是刮除多余溶液(如图1中IV所示),将聚二甲基硅氧烷微针模具在避光条件下,置于3-5℃的温度下进行干燥(如图1中V所示),其中实施例1、实施例4-8以及对比例1-12的干燥温度均为4℃,实施例2的干燥温度为3℃,实施例3的干燥温度为5℃。最后,用镊子小心地将模具上的微针剥离脱模,即得用于抗皱嫩肤的微针贴(如图1中VI所示)。
表1:微针中各个活性成分的含量表
注:“/”表示未添加该成分。
本发明实施例1制备得到的微针贴(眼膜)放置于黑色背景上,通过光学摄像头拍摄,得到微针贴的宏观图像如图2所示,所制备的微针贴为圆弧形,且只有在中间部位分布有微针。该微针贴还包括贴膜,所述微针贴通过所述基底固定于所述贴膜上,且所述贴膜可与该微针贴的作用部位黏贴固定。实施例2-8制备得到的微针贴(眼膜)的宏观图像与图2类似,为简略起见,不再赘述。
实验例
本实验例对上述制备得到的微针进行性能和效果实验验证。
一、性能实验
1、形貌观察
将实施例1-8制备的微针贴分别放置于生物显微镜载物台上,调整显微镜放大倍数为30倍,可以通过显微镜拍摄软件获取微针的微观图像。图3示出了本发明实施例1的微针针尖的显微图像。从图中可以看出,所制备的微针针尖为尖锐的圆锥形,且针尖结构较为完整,能赋予微针针尖较好的性能去刺穿角质层,实现活性成分的皮下输送,发挥微针贴较好的美容效果。实施例2-8中的微针针尖显微图像与图3类似,为简略起见,不再重复。
2、力学性能测定
将实施例1-8中所制备的微针贴分别放置于万能测力机的测试台上,微针面朝上,并记录压缩过程中的力学性能的变化。微针长约200μm,因此,设置压缩距离为微针长的一半,约100μm。图4示出了实施例1中所制备的微针贴的微针的力学性能评价结果,从图中可以看到,每根微针的最大屈折力学性能均超过0.7N,大于刺穿角质层所需最小力(0.045N)。这充分说明所制备的微针贴的微针具有足够的力学性能来刺穿角质层,能有效实现活性成分的皮下输送。实施例2-8中所制备的微针也具有同样的力学性能,为简略起见,不再重复。
二、效果实验
1、方法
选取200名受试者,男女各半,年龄为30~60,无皮肤病过敏史,符合受试者志愿入选标准,将受试者平均随机分为20组,每组10人。以实施例1-8和对比例1-12制备的微针作为受试产品,分别作用于各组受试者。
使用方法:将微针贴(眼贴膜)贴于眼周皱纹处,每天晚上贴覆1次,60分钟后揭下,试用28天。
疗效标准如下:
效果显著:皱纹消失;
有效:皱纹变浅;
无效:皮肤无明显变化。
2、结果
28天后,统计受试者的反馈情况,结果如表2所示。
表2:受试者使用实施例和对比例的微针贴(眼膜)28天后的结果
组别 | 效果显著人数 | 有效人数 | 无效人数 | 总有效率 |
实施例1 | 8 | 1 | 1 | 90% |
实施例2 | 5 | 2 | 3 | 70% |
实施例3 | 8 | 1 | 1 | 90% |
实施例4 | 6 | 2 | 2 | 80% |
实施例5 | 9 | 0 | 1 | 90% |
实施例6 | 7 | 1 | 2 | 80% |
实施例7 | 8 | 1 | 1 | 90% |
实施例8 | 9 | 0 | 1 | 90% |
对比例1 | 0 | 4 | 6 | 40% |
对比例2 | 1 | 4 | 5 | 50% |
对比例3 | 1 | 3 | 6 | 40% |
对比例4 | 2 | 2 | 6 | 40% |
对比例5 | 1 | 3 | 6 | 40% |
对比例6 | 0 | 4 | 6 | 40% |
对比例7 | 1 | 4 | 5 | 50% |
对比例8 | 0 | 4 | 6 | 40% |
对比例9 | 0 | 3 | 7 | 30% |
对比例10 | 2 | 2 | 6 | 40% |
对比例11 | 2 | 4 | 4 | 60% |
对比例12 | 1 | 3 | 6 | 40% |
从表2可以看出,实施例1-8这几组的受试者的效果显著人数明显高于其他组,且总有效率均达到了70%以上;而对比例1-12这几组的受试者的效果显著人数明显降低,总有效率基本不到60%。
从表2还可以看出,微针中各个活性成分的含量变化时,其效果也会有一定的变化。在考虑到微针的技术效果和成本效益的基础上,各活性成分的适宜含量分别为:5.0~15.0份透明质酸钠、0.5~1.5份重组胶原蛋白、2.0~8.0份烟酰胺、2.0~8.0份维生素C、0.1~0.3份蓝铜胜肽。而透明质酸钠作为微针的主要赋形材料,其含量应该与各活性成分相适宜,过多可能导致溶液过于黏稠,过少则不能赋予微针相应的形状,从而都不能形成良好的微针。在考虑到效果和成本的基础上,认为透明质酸钠的适宜含量为5.0~15.0g。
与实施例1相比,对比例5省略了实施例1中的重组胶原蛋白,对比例6省略了实施例1中的烟酰胺,对比例7省略了实施例1中的维生素C,对比例8省略了实施例1中的蓝铜胜肽。结果显示,无论省略了上述四种活性成分任一种时,所制备的微针的效果都明显降低,这说明这四种成分不可或缺。
与实施例1相比,对比例9中的重组胶原蛋白被替换成同样具有抗皱作用的白藜芦醇;对比例10中的烟酰胺被替换成同样具有抗皱作用的视黄醇A;对比例11中的维生素C被替换成同样具有抗皱作用的维生素E;而对比例12中的蓝铜胜肽被替换成同样具有抗皱作用的肌肽。结果显示,对比例9-12这几组的受试者的效果显著人数明显降低,每组仅1-2名受试者反馈有显著效果,甚至无人反馈有显著效果。也就是说,当将上述四种活性成分任一种替换为别的活性成分时,所制备的微针的效果会明显降低。这说明这四种成分不可替代,证明上述四种活性成分产生了协同作用。
本发明并不局限于上述实施方式,若对本发明的各种改动或变型不脱离本发明的精神和范围,这些改动和变型属于本发明的权利要求和等同技术范围之类,则本发明也意图包含这些改动和变动。
Claims (10)
3.权利要求1-2任一项所述的用于抗皱嫩肤的微针的制备方法,包括以下步骤:
(1)微针溶液的制备:
将所述活性成分加入水中,充分搅拌至溶解,配制成微针溶液;
(2)微针的制备:
将上述微针溶液转移至微针模具中;将模具放入真空干燥箱中抽真空,以去除气泡;干燥;将微针从模具上剥离脱模,即得微针。
4.根据权利要求3所述的制备方法,其特征在于,所述模具为聚二甲基硅氧烷微针模具。
5.根据权利要求3所述的制备方法,其特征在于,在步骤(2)中,抽真空之后,去除溢出模具孔槽的溶液,再进行干燥。
6.根据权利要求3所述的制备方法,其特征在于,在步骤(2)中,所述抽真空的参数条件为:真空度为-60~-90kPa,保持3±1小时。
7.根据权利要求3-5任一项所述的制备方法,其特征在于,在步骤(2)中,所述干燥步骤在避光和3~5℃的环境中进行。
8.根据权利要求1或2所述的微针在美容产品中的应用。
9.根据权利要求8所述的应用,其特征在于,所述美容产品为微针贴,所述微针贴包括基底和若干所述微针,所述微针呈圆锥状,并与所述基底一体成型。
10.根据权利要求9所述的应用,其特征在于,所述微针贴还包括贴膜,所述微针贴通过所述基底固定于所述贴膜上,且所述贴膜可与该微针贴的作用部位黏贴固定。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210665048.9A CN114903799A (zh) | 2022-06-14 | 2022-06-14 | 一种用于抗皱嫩肤的微针及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210665048.9A CN114903799A (zh) | 2022-06-14 | 2022-06-14 | 一种用于抗皱嫩肤的微针及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114903799A true CN114903799A (zh) | 2022-08-16 |
Family
ID=82771110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210665048.9A Pending CN114903799A (zh) | 2022-06-14 | 2022-06-14 | 一种用于抗皱嫩肤的微针及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114903799A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110051572A (ko) * | 2009-11-10 | 2011-05-18 | (주)아모레퍼시픽 | 항노화용 또는 주름개선용 화장료 조성물 |
CN114028264A (zh) * | 2021-11-26 | 2022-02-11 | 广州贝奥吉因生物科技股份有限公司 | 一种用于祛痘修护的微针贴及其制备方法和应用 |
CN114259458A (zh) * | 2022-01-04 | 2022-04-01 | 上海忱扬生物科技有限公司 | 一种具有抗衰功效的超氧化物岐化酶可溶性微针贴片 |
CN114306095A (zh) * | 2021-12-16 | 2022-04-12 | 中科(广州)再生医学科技开发有限公司 | 一种用于抗皱保湿的微针贴及其制备方法和应用 |
-
2022
- 2022-06-14 CN CN202210665048.9A patent/CN114903799A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110051572A (ko) * | 2009-11-10 | 2011-05-18 | (주)아모레퍼시픽 | 항노화용 또는 주름개선용 화장료 조성물 |
CN114028264A (zh) * | 2021-11-26 | 2022-02-11 | 广州贝奥吉因生物科技股份有限公司 | 一种用于祛痘修护的微针贴及其制备方法和应用 |
CN114306095A (zh) * | 2021-12-16 | 2022-04-12 | 中科(广州)再生医学科技开发有限公司 | 一种用于抗皱保湿的微针贴及其制备方法和应用 |
CN114259458A (zh) * | 2022-01-04 | 2022-04-01 | 上海忱扬生物科技有限公司 | 一种具有抗衰功效的超氧化物岐化酶可溶性微针贴片 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Intini et al. | 3D-printed chitosan-based scaffolds: An in vitro study of human skin cell growth and an in-vivo wound healing evaluation in experimental diabetes in rats | |
CN107184417B (zh) | 可溶性微针贴片及其制备方法 | |
US11801371B2 (en) | Microneedle device | |
CN105025976B (zh) | 微型针、微型针的制造模具和制造方法 | |
CN107073251A (zh) | 用于减少皱纹的微针片及形成方法 | |
US20210212810A1 (en) | Multi-layer skin constructs and methods of making and using the same | |
KR20170113555A (ko) | 다층 피부 대체재 산물 및 그의 제조 및 사용 방법 | |
WO2017130793A1 (ja) | マイクロニードルアレイ、マイクロニードルシート | |
CN114306095A (zh) | 一种用于抗皱保湿的微针贴及其制备方法和应用 | |
CN109044907A (zh) | 一种无痛透皮美容微针贴及其制备方法 | |
CN114028264A (zh) | 一种用于祛痘修护的微针贴及其制备方法和应用 | |
CN106420371B (zh) | 一种肌肤护理用丝素蛋白水凝胶及其制备方法 | |
KR20160056005A (ko) | 단일 또는 이종의 피부활성성분의 공급제어 기능을 가지는 하이드로겔 마스크팩의 제조방법 | |
KR20160056004A (ko) | 기능성이 강화된 하이드로겔 마스크팩의 제조방법 | |
CN114939080A (zh) | 一种用于祛黑美白的微针及其制备方法和应用 | |
Sadeghi et al. | Multilayered 3-D nanofibrous scaffold with chondroitin sulfate sustained release as dermal substitute | |
CN118302143A (zh) | 经皮吸收率优异的透明质酸膜及其制备方法 | |
CN110947088A (zh) | 护眼组合贴片及其制备方法 | |
CN115430031B (zh) | 一种多功能美容微针贴片及其批量化制备方法 | |
CN114903799A (zh) | 一种用于抗皱嫩肤的微针及其制备方法和应用 | |
KR101698053B1 (ko) | 엠보싱 형상 표면을 가지는 하이드로겔 마스크팩의 제조방법 | |
TWI609699B (zh) | 絲質水凝膠組成物及絲質水凝膠面膜 | |
JP5935181B2 (ja) | 創傷治癒用の生体材料およびその調製 | |
KR102334072B1 (ko) | 경피 전달용 색소 마이크로구조체 | |
CN113384485A (zh) | 一种复合结构的可溶性玻尿酸微针眼膜及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220816 |